Clinical Trial Update: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing Mosunetuzumab-Lenalidomide to the investigator's choice in relapsed or refractory marginal zone lymphoma; recruitment is ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Mosunetuzumab (mosunetuzumab)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Marginal Zone Lymphoma | Phase 3 | Status: RECRUITING